Market Research Consumer Goods Market Research Consumer Goods & Retailing Market Research Retailing Market Research Drug Stores Market Research

Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,749 187 Pages 360iResearch January, 2024 IRE18417858
Best Price Guarantee
Price from $4,749
Length 187 Pages
Publisher 360iResearch
Published Date January, 2024
SKU IRE18417858

Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030


The Alpha Glucosidase Inhibitors Market size was estimated at USD 616.76 million in 2023 and expected to reach USD 703.76 million in 2024, at a CAGR 14.50% to reach USD 1,591.49 million by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha Glucosidase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Glucosidase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..

Market Segmentation & Coverage

This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug class

Acarbose (Precose)
  • Miglitol (Glyset)
  • Voglibose
  • Distribution Channel

    Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • End-Users

    Home Healthcare
  • Hospitals & Clinics
  • Specialty Diabetes Centers
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Alpha Glucosidase Inhibitors Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Glucosidase Inhibitors Market?
    3. What are the technology trends and regulatory frameworks in the Alpha Glucosidase Inhibitors Market?
    4. What is the market share of the leading vendors in the Alpha Glucosidase Inhibitors Market?
    5. Which modes and strategic moves are suitable for entering the Alpha Glucosidase Inhibitors Market?


    Note: PDF & Excel + Online Access - 1 Year


    • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Alpha Glucosidase Inhibitors Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Prevalence of type 2 diabetes and need for improved care
    5.1.1.2. Government initiatives and policies encouraging diabetes management
    5.1.1.3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
    5.1.2. Restraints
    5.1.2.1. Difficulties of API approval and dosing regimen
    5.1.3. Opportunities
    5.1.3.1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
    5.1.3.2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
    5.1.4. Challenges
    5.1.4.1. Concerns associated with gastrointestinal side effects and drug interactions
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Alpha Glucosidase Inhibitors Market, by Drug class
    6.1. Introduction
    6.2. Acarbose (Precose)
    6.3. Miglitol (Glyset)
    6.4. Voglibose
    7. Alpha Glucosidase Inhibitors Market, by Distribution Channel
    7.1. Introduction
    7.2. Hospital Pharmacies
    7.3. Online Pharmacies
    7.4. Retail Pharmacies
    8. Alpha Glucosidase Inhibitors Market, by End-Users
    8.1. Introduction
    8.2. Home Healthcare
    8.3. Hospitals & Clinics
    8.4. Specialty Diabetes Centers
    9. Americas Alpha Glucosidase Inhibitors Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Alpha Glucosidase Inhibitors Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. Alkem Laboratories Ltd.
    13.1.2. Avecia Healthcare
    13.1.3. Bal Pharma Ltd.
    13.1.4. Bayer AG
    13.1.5. Biocon
    13.1.6. BioVision Inc. by Abcam US Group Holdings Inc.
    13.1.7. Cipla Ltd.
    13.1.8. Elder Pharmaceuticals Ltd.
    13.1.9. Empros Pharma AB
    13.1.10. Glenmark Pharmaceuticals Ltd.
    13.1.11. Lunan Pharmaceuticals Group
    13.1.12. Manus Aktteva Biopharma LLP
    13.1.13. Merck KGaA
    13.1.14. Micro Labs Ltd.
    13.1.15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
    13.1.16. Novo Nordisk A/S
    13.1.17. Samex Overseas
    13.1.18. Sanofi S.A.
    13.1.19. Shenzhen Haorui Pharmatech Co., Ltd.
    13.1.20. Straight Healthcare
    13.1.21. Strides Arcolab Limited
    13.1.22. Sun Pharmaceutical Industries Ltd.
    13.1.23. Takeda Pharmaceutical Co. Ltd.
    13.1.24. Torrent Pharmaceuticals Ltd.
    13.1.25. Wockhardt Ltd.
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
    FIGURE 2. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
    FIGURE 7. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 8. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 10. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
    FIGURE 12. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

    $4,749
    $5,749
    $6,749
    $8,749

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings